NCT00092534View on ClinicalTrials.gov

Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)

PHASE3CompletedINTERVENTIONAL
Enrollment

12,167

Participants

Timeline

Start Date

June 14, 2002

Primary Completion Date

July 31, 2007

Study Completion Date

June 13, 2025

Conditions
Cervical CancerGenital Warts
Interventions
BIOLOGICAL

Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine

A 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.

BIOLOGICAL

Matching Placebo

A placebo 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092534 - Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) | Biotech Hunter | Biotech Hunter